IM Cannabis Corp. publishes MD&A report for Q3 2025
IM Cannabis Corp. released its Q3 2025 MD&A report, detailing financial and operational results. The company emphasized its focus on international medical cannabis operations, with shares now trading solely on Nasdaq after delisting from the Canadian Securities Exchange. Efforts continue in expanding market presence and product offerings, with ongoing activities in Israel and Europe. The report was published on November 13, 2025.
IM Cannabis Corp. reported on its consolidated financial condition and operating results for the three and nine months ended September 30, 2025. The company highlighted its ongoing operations in the international medical cannabis industry, with its common shares now exclusively trading on the Nasdaq Capital Market following a voluntary delisting from the Canadian Securities Exchange, effective June 2, 2025. IM Cannabis continues to focus on expanding its presence in key geographies and new markets, introducing new product offerings, and maintaining a high-quality, reliable supply across its brands. The report also referenced discontinued operations and ongoing activities involving its Israeli subsidiaries and European operations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IM Cannabis Corp. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
